OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Commerce. All rights reserved.
Thomson Reuters Bioworld report tracks biosimilar development
Using such resources as Cortellis Competitive Intelligence, Newport Premium and the company’s own Life Sciences Professional Services, Thomson Reuters Bioworld (Philadelphia) has issued a new report tracking the development of biosimilars globally. Entitled “Biosimilars: A Global Perspetive of a New Market—Opportunities, Threats and Critical Strategies 2014,” the report finds that South Korea is a “notable standout” for its ambitious development programs; India is also very active. There are 245 companies or research institutes worldwide pursuing development programs. Like drug development generally, however, it remains to be seen how many programs will be able to run the course all the way through approval, especially for the US market where FDA is still assembling its approval program.
According to Thomson Reuters:
“Governments and payers are counting on biosimilars to dramatically change drug development and patient costs by reducing the price tag of important biologics and increasing access to life-saving drugs," said Jon Brett-Harris, managing director of Thomson Reuters Life Sciences. "For this to happen, biosimilars must deliver the power of the reference drugs at a price developing countries can afford and gain the confidence of the marketplace. They have to create their own market."
Details on the report are available here.